- Investing Ideas
- U.S. Pharmaceuticals & Biotech Sustainable Track Record
U.S. Pharmaceuticals & Biotech Sustainable Track Record
Results
13
Companies which have reinvested earnings to sustain 10% yearly growth over 5 years.
13 companies
ACADIA Pharmaceuticals
Market Cap: US$4.7b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$28.80
7D
9.3%
1Y
21.0%
CorMedix
Market Cap: US$590.0m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.41
7D
3.1%
1Y
-38.0%
Incyte
Market Cap: US$24.4b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$119.80
7D
-5.7%
1Y
54.3%
Protalix BioTherapeutics
Market Cap: US$191.0m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.44
7D
7.5%
1Y
64.9%
TG Therapeutics
Market Cap: US$6.9b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$49.88
7D
-6.7%
1Y
80.1%
CareDx
Market Cap: US$2.4b
Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
CDNA
US$45.50
7D
28.5%
1Y
247.3%
Eli Lilly
Market Cap: US$994.9b
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
LLY
US$1,169.86
7D
-3.3%
1Y
56.7%
Rigel Pharmaceuticals
Market Cap: US$716.0m
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
RIGL
US$40.48
7D
3.6%
1Y
35.8%
Aurinia Pharmaceuticals
Market Cap: US$1.9b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$15.19
7D
0.07%
1Y
30.8%
Exelixis
Market Cap: US$14.1b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$56.70
7D
2.5%
1Y
50.4%
Medpace Holdings
Market Cap: US$16.1b
Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
MEDP
US$587.75
7D
0.5%
1Y
36.6%
Earth Science Tech
Market Cap: US$26.5m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.093
7D
-15.5%
1Y
-46.9%
CapForce
Market Cap: US$84.2m
A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.
CFOR
US$5.00
7D
-72.2%
1Y
n/a